• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

Introduction to (R,R)-Palonosetron Hydrochloride (CAS No. 135729-75-8)

(R,R)-Palonosetron Hydrochloride, with the chemical formula CAS No. 135729-75-8, is a highly specialized pharmaceutical compound that has garnered significant attention in the field of chemobiology and medicinal chemistry. This compound belongs to the class of selective serotonin 5-HT3 receptor antagonists, which are widely utilized in the management of nausea and vomiting induced by chemotherapy, radiation therapy, and surgery. The unique stereochemical configuration of (R,R)-Palonosetron Hydrochloride, specifically its (R,R) enantiomeric form, has been identified as a critical factor in its enhanced pharmacological efficacy and reduced side effects compared to its predecessor, Palonosetron.

The development of (R,R)-Palonosetron Hydrochloride represents a significant advancement in the treatment of chemotherapy-induced nausea and vomiting (CINV). Unlike earlier 5-HT3 receptor antagonists, which often exhibited limited duration of action and a higher propensity for peripheral side effects, (R,R)-Palonosetron Hydrochloride has demonstrated a prolonged duration of effect. This extended action is attributed to its higher affinity for the 5-HT3 receptor and its improved pharmacokinetic profile. The compound's ability to effectively block the action of serotonin at the synaptic cleft in the central nervous system and peripheral nervous system results in significant attenuation of emetic responses.

Recent studies have highlighted the importance of stereochemistry in the pharmacological activity of 5-HT3 receptor antagonists. The (R,R) configuration of (R,R)-Palonosetron Hydrochloride has been found to be more potent and selective compared to other enantiomers. This stereochemical specificity allows for a more targeted interaction with the 5-HT3 receptor, leading to improved therapeutic outcomes. The hydrochloride salt form enhances the solubility and bioavailability of the compound, making it more suitable for intravenous administration.

One of the most compelling aspects of (R,R)-Palonosetron Hydrochloride is its efficacy in patients who have developed tolerance to other 5-HT3 receptor antagonists. This resilience against tolerance is particularly important for patients undergoing multiple cycles of chemotherapy, where maintaining effective anti-emetic therapy is crucial. Clinical trials have consistently shown that (R,R)-Palonosetron Hydrochloride provides superior control over nausea and vomiting compared to standard-of-care treatments.

The pharmacological profile of (R,R)-Palonosetron Hydrochloride has also been studied in various patient populations, including pregnant women and elderly patients. The compound has demonstrated a favorable safety profile in these groups, with minimal teratogenic effects observed in animal studies and no significant adverse events reported in human trials involving pregnant women. Additionally, elderly patients have shown similar efficacy and safety profiles compared to younger adults, making it a versatile therapeutic option across different age groups.

Advances in drug delivery systems have further enhanced the therapeutic potential of (R,R)-Palonosetron Hydrochloride. Formulations such as extended-release injectables have been developed to provide even longer-lasting protection against nausea and vomiting. These formulations are particularly beneficial for patients undergoing prolonged or multiple-day chemotherapy regimens, ensuring continuous anti-emetic coverage.

The mechanism of action of (R,R)-Palonosetron Hydrochloride involves competitive binding to the 5-HT3 receptors located on both central nervous system neurons and peripheral vagal nerve endings. By blocking serotonin from binding to these receptors, the compound effectively prevents the stimulation that would otherwise lead to nausea and vomiting. This mechanism is particularly effective because it targets both central and peripheral pathways involved in emesis.

Recent research has also explored the potential synergistic effects of combining (R,R)-Palonosetron Hydrochloride with other anti-emetic agents. Studies have shown that co-administration with dexamethasone can further enhance anti-emetic efficacy while reducing the risk of side effects such as constipation and delayed gastric emptying. This combination therapy approach represents an important advancement in managing CINV for patients receiving highly emetic chemotherapy regimens.

The synthesis and characterization of (R,R)-Palonosetron Hydrochloride have been subjects of extensive research in medicinal chemistry. The compound's synthesis involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced spectroscopic techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry are employed to confirm the structural integrity of the final product.

The industrial production of (R,R)-Palonosetron Hydrochloride adheres to stringent quality control measures to ensure consistency and reliability across batches. Good Manufacturing Practices (GMP) are strictly followed during production to minimize variability and ensure that each batch meets predefined quality standards. This rigorous quality control ensures that healthcare providers can confidently administer (R,R)-Palonosetron Hydrochloride with predictable efficacy.

The regulatory landscape for (R,R)-Palonosetron Hydrochloride has evolved alongside advancements in our understanding of its pharmacology and clinical benefits. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted approval for various formulations based on comprehensive clinical data demonstrating their safety and efficacy. These approvals underscore the growing recognition of (R,R)-Palonosetron Hydrochloride as a cornerstone therapy for managing CINV.

Future directions in research on (R,R)-Palonosetron Hydrochloride include exploring its potential applications beyond CINV management. Preliminary studies suggest that it may have utility in treating other conditions involving serotonin receptors, such as irritable bowel syndrome (IBS). Additionally, research into novel delivery systems, such as oral formulations or nanoparticles, could further expand its therapeutic applications.

In conclusion, (R,R)-Palonosetron Hydrochloride represents a significant advancement in anti-emetic therapy due to its prolonged duration of action, improved efficacy compared to earlier agents, and favorable safety profile. Its unique stereochemical configuration, enhanced solubility due to its hydrochloride salt form, and ability to overcome tolerance make it an invaluable tool in managing chemotherapy-induced nausea and vomiting. As research continues to uncover new applications and delivery methods, (R,R)-Palonosetron Hydrochloride is poised to remain at the forefront of therapeutic options for patients experiencing severe nausea and vomiting.

• 135729-78-1((S)-N-(1-Azabicyclo2.2.2oct-3-yl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamide)
• 135729-56-5(Palonosetron)
• 149653-99-6((5R)-3-(3R)-1-azabicyclo2.2.2octan-3-yl-3-azatricyclo7.3.1.0,5,13trideca-1(13),9,11-trien-2-one)
• 135729-61-2(Palonosetron)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)